What's new? Log in Free sign up

NewAmsterdam Pharma (NAMS)

Company Profile

Company profile

Ticker

NAMS, NAMSW

Exchange

Website

www.newamsterdampharma.com

CEO

Dr. Michael Harvey Davidson FACC, Facp., M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

NewAmsterdam Pharma Co B.V.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

NAMS stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Prospectus supplement for primary offering

Registration of additional securities for an S-3

Prospectus supplement for primary offering

Regulation FD Disclosure

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating

Quarterly report

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Annual report (foreign) (amended)

Latest ownership filings

View all

Change in insider ownership

Change in insider ownership

BCLS II Investco, LP

Change in insider ownership

Forbion Capital Fund IV Cooperatief U.A.

Frazier Life Sciences X, L.P.

Change in insider ownership

Change in insider ownership

Change in insider ownership

Change in insider ownership

Financial summary

Financial statements Chart NAMS financial data

Quarter (USD)	Sep 24	Dec 23	Dec 22	Nov 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Nov 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

NAMS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	107	96	+11.5%
Opened positions	24	24	–
Closed positions	13	10	+30.0%
Increased positions	44	30	+46.7%
Reduced positions	17	17	–

13F shares	Current	Prev Q	Change
Total value	1.27 tn	1.38 tn	-7.9%
Total shares	109.63 mm	109.46 mm	+0.2%
Total puts	3.60 k	3.20 k	+12.5%
Total calls	65.70 k	900.00	+7200.0%
Total put/call ratio	0.1	3.6	-98.5%

Largest owners	Shares	Value	Change
Frazier Life Sciences Management	12.86 mm	$213.40 bn	+5.1%
Capital Fund IV Cooperatief U.A. Forbion	11.83 mm	$163.87 mm	0.0%
FCPM Iii Services B.V.	11.83 mm	$196.40 bn	0.0%
Bain Capital Life Sciences Investors	10.47 mm	$173.87 bn	0.0%
Ra Capital Management	8.06 mm	$133.86 bn	0.0%
Viking Global Investors	8.02 mm	$133.21 bn	0.0%
Frazier Life Sciences X	7.30 mm	$79.51 mm	0.0%
BCLS II Investco	5.38 mm	$60.75 mm	0.0%
Morningside Venture Investments	4.06 mm	$40.57 mm	0.0%
Frazier Lifesciences Sponsor	3.97 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
AMGN Amgen	0.00	-4.91 mm	EXIT
Millennium Management	16.75 k	-1.15 mm	-98.6%
Siren, L.L.C.	920.56 k	+920.56 k	NEW
Artal	0.00	-800.00 k	EXIT
Woodline Partners	1.16 mm	+681.29 k	+140.9%
Frazier Life Sciences Management	12.86 mm	+628.25 k	+5.1%
JHG Janus Henderson	1.54 mm	+520.77 k	+51.1%
Polar Capital	1.51 mm	+502.41 k	+50.1%
Rock Springs Capital Management	353.32 k	+353.32 k	NEW
Pictet Asset Management Holding	1.02 mm	+333.17 k	+48.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

NAMS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	25.4452	56,506	1.44 mm	10,851,996
18 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	26.5496	46,210	1.23 mm	10,908,502
18 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	25.7172	54,518	1.40 mm	10,954,712
17 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	26.4463	47,736	1.26 mm	11,009,230
17 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	25.6019	66,648	1.71 mm	11,056,966
16 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	25	1,096	27.40 k	11,123,614
13 Dec 24	Bain Capital Life Sciences Investors	Pre-Funded Warrant Ordinary Shares	Buy	Acquire P	Yes	No	24.4999	1,632,653	40.00 mm	1,632,653
13 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	25.0106	25,751	644.05 k	11,124,710
12 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	26.1763	25,963	679.62 k	11,150,461
12 Dec 24	ForGrowth NAP B.V.	Ordinary Shares	Sell	Dispose S	Yes	Yes	25.25	140,048	3.54 mm	11,176,424

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.

Reported Earlier, NewAmsterdam Pharma Prices $416.5M Upsized Public Offering At $24.50/Share to Advance Cardiovascular Treatments

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, "NewAmsterdam" or the "Company"))), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease

Scotiabank Maintains Sector Outperform on NewAmsterdam Pharma, Raises Price Target to $47

Scotiabank analyst George Farmer maintains NewAmsterdam Pharma (NASDAQ:NAMS) with a Sector Outperform and raises the price target from $35 to $47.

Top 3 Health Care Stocks That May Collapse This Quarter

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Press releases

From Benzinga Pro

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, "NewAmsterdam" or the "Company")), a late-stage, clinical biopharmaceutical company developing oral,

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS, "NewAmsterdam" or the "Company")), a late-stage, clinical biopharmaceutical company developing oral,

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.